BRPI1012170A2 - formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido. - Google Patents

formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.

Info

Publication number
BRPI1012170A2
BRPI1012170A2 BRPI1012170A BRPI1012170A BRPI1012170A2 BR PI1012170 A2 BRPI1012170 A2 BR PI1012170A2 BR PI1012170 A BRPI1012170 A BR PI1012170A BR PI1012170 A BRPI1012170 A BR PI1012170A BR PI1012170 A2 BRPI1012170 A2 BR PI1012170A2
Authority
BR
Brazil
Prior art keywords
ingested
sublingual
formulation
reducing
achieve
Prior art date
Application number
BRPI1012170A
Other languages
English (en)
Inventor
Alistar Cumming
David Kannar
Lance Sparrow
Original Assignee
Lingual Consegna Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2009902280A external-priority patent/AU2009902280A0/en
Application filed by Lingual Consegna Pty Ltd filed Critical Lingual Consegna Pty Ltd
Publication of BRPI1012170A2 publication Critical patent/BRPI1012170A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1012170A 2009-05-20 2010-05-20 formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido. BRPI1012170A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2009902280A AU2009902280A0 (en) 2009-05-20 Improved therapeutic formulations
PCT/AU2010/000594 WO2010144943A1 (en) 2009-05-20 2010-05-20 Buccal and/or sublingual therapeutic formulation

Publications (1)

Publication Number Publication Date
BRPI1012170A2 true BRPI1012170A2 (pt) 2016-03-29

Family

ID=43355588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012170A BRPI1012170A2 (pt) 2009-05-20 2010-05-20 formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.

Country Status (9)

Country Link
US (1) US20120058962A1 (pt)
EP (1) EP2437730A4 (pt)
JP (1) JP2012527406A (pt)
CN (1) CN102612363A (pt)
AU (3) AU2010262738A1 (pt)
BR (1) BRPI1012170A2 (pt)
CA (1) CA2761538A1 (pt)
MX (1) MX2011012078A (pt)
WO (1) WO2010144943A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9254294B2 (en) 2003-02-24 2016-02-09 Pharmaceutical Productions Inc. Transmucosal hormone delivery system
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
US8808736B2 (en) 2011-02-11 2014-08-19 Zx Pharma, Llc Enteric coated multiparticulate controlled release peppermint oil composition and related methods
US8911780B2 (en) 2011-02-11 2014-12-16 Zx Pharma, Llc Multiparticulate L-menthol formulations and related methods
RU2590979C2 (ru) 2011-02-11 2016-07-10 ЗедЭкс ФАРМА, ЭлЭлСи Составы l-ментола, состоящие из множества частиц, и связанные с ними способы
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
ES2885523T3 (es) 2011-11-23 2021-12-14 Therapeuticsmd Inc Formulaciones y terapias de reposición hormonal de combinación naturales
KR20220042485A (ko) 2012-01-16 2022-04-05 엘라자베스 맥켄나 간 질환들 및 장애들의 치료를 위한 조성물들 및 방법들
US12268718B2 (en) 2012-01-16 2025-04-08 Labyrinth Holdings Llc Control of cellular redox levels
CN102525979B (zh) * 2012-02-07 2013-03-27 海南卫康制药(潜山)有限公司 一种小儿布洛芬组合物
CN104507495A (zh) * 2012-04-23 2015-04-08 巴拉特生物技术国际有限公司 轮状病毒疫苗组合物及其制备方法
JP5877778B2 (ja) * 2012-05-28 2016-03-08 株式会社ホットアルバム炭酸泉タブレット 錠剤の製造方法及び錠剤
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
EP2898073A4 (en) 2012-09-21 2016-03-23 Elizabeth Mckenna Naturally-occurring CPG-oligonucleotide compositions and therapeutic applications thereof
BR112015010703B1 (pt) 2012-11-13 2021-02-17 Invictus Biotechnology Pty Ltd uso de uma composição farmacêutica e composição farmacêutica
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
RS58325B1 (sr) 2013-04-23 2019-03-29 Zx Pharma Llc Enterosolventno obloženi višečestični preparat sa proteinskom sub-oblogom
JP2016517883A (ja) 2013-05-03 2016-06-20 オレゴン ヘルス アンド サイエンス ユニバーシティー Ｘ連鎖副腎白質ジストロフィーの処置におけるソベチロムの使用
WO2014195032A1 (en) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
JP7077589B2 (ja) * 2016-11-29 2022-05-31 大正製薬株式会社 固形製剤
WO2019246074A1 (en) * 2018-06-18 2019-12-26 Synergistic Therapeutics, Llc Sublingual antidepressant and antianxiety tablet
GB2604037A (en) * 2019-07-28 2022-08-24 Banerjee Debasish Enhancing drug activity through accentuated buccal/sublingual administration
US20230338320A1 (en) * 2019-11-22 2023-10-26 Wockhardt Limited Oral film composition comprising levothyroxine
WO2022234593A1 (en) * 2021-05-02 2022-11-10 Zenvision Pharma Llp Sublingual compositions comprising nintedanib or salt thereof
WO2026022657A1 (en) * 2024-07-21 2026-01-29 Cology Biosciences Private Limited Novel sublingual compositions for the treatment of fibrotic diseases and hypertensive diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6064915A (ja) * 1983-09-20 1985-04-13 Grelan Pharmaceut Co Ltd 軟質な口腔製剤
GB8426152D0 (en) * 1984-10-16 1984-11-21 Reckitt & Colmann Prod Ltd Medicinal compositions
US5244668A (en) * 1988-10-14 1993-09-14 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
DE3927723A1 (de) * 1989-01-26 1990-08-02 Ulrich Prof Dr Speck N - acetylglucosamin zur buccalen anwendung
FR2718020B1 (fr) * 1994-04-01 1996-05-31 Biotec Centre Sa Composition galénique mucoadhésive hétérofonctionnelle.
PT814789E (pt) * 1995-03-02 2003-09-30 Scherer Technologies Inc R P Composicoes farmaceuticas compreendendo inibidores de monoamina-oxidase b
TW442287B (en) * 1995-06-13 2001-06-23 American Home Produits Corp Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
EP0893992B1 (en) * 1996-04-16 2004-03-03 Novartis Consumer Health S.A. Fast disintegrating oral dosage form
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
AU2002327418A1 (en) * 2001-08-01 2003-02-17 Bristol-Myers Squibb Company Taste masking composition
US6884790B2 (en) * 2002-09-09 2005-04-26 Josef Pitha Verifiable absorption drug delivery form based on cyclodextrins
SE0300831D0 (sv) * 2003-03-26 2003-03-26 Pharmacia Ab New formulations and use therof
ITRM20030288A1 (it) * 2003-06-10 2004-12-11 Valerio Cioli Somministrazione sublinguale di antinfiammatori non steroidei (fans)
GB0320854D0 (en) * 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
GB0423800D0 (en) * 2004-10-27 2004-12-01 Orexo Ab New pharmaceutical formulations
WO2006101536A1 (en) * 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
RU2406480C2 (ru) * 2005-04-08 2010-12-20 Озфарма Пти Лтд Трансбуккальная система доставки
JP2008546786A (ja) * 2005-06-23 2008-12-25 シェーリング コーポレイション Ｐｄｅ５インヒビターの迅速吸収性経口処方物
AU2006275405A1 (en) * 2005-08-01 2007-02-08 Teva Pharmaceutical Industries Ltd. Tizanidine compositions and methods of treatment using the compositions
US8007783B2 (en) * 2006-08-22 2011-08-30 Carl Miller Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine

Also Published As

Publication number Publication date
CN102612363A (zh) 2012-07-25
AU2018217251A1 (en) 2018-08-30
AU2010262738A1 (en) 2011-10-13
EP2437730A1 (en) 2012-04-11
US20120058962A1 (en) 2012-03-08
CA2761538A1 (en) 2010-12-23
AU2016238901A1 (en) 2016-10-20
MX2011012078A (es) 2012-03-14
WO2010144943A1 (en) 2010-12-23
EP2437730A4 (en) 2014-02-26
JP2012527406A (ja) 2012-11-08

Similar Documents

Publication Publication Date Title
BRPI1012170A2 (pt) formulação e/ou sublingual e método para reduzir a quantidade de composto ativo usado para alcançar um efeito em um paciente em comparação com um composto típico que é ingerido.
HUS1900031I1 (hu) Hatóanyagok légúti beadása
BRPI1013503A2 (pt) formulação de iniciador não cromado que inibe corrosão, e, estrutura
BR112013030599A2 (pt) núcleo absorvente para artigos absorventes descartáveis
CO6801721A2 (es) Combinaciones de principios activos que comprenden piriditeilbenzamidas y otros principios activos
BR112012019529A2 (pt) inibidores de d-nitrosoglutationa redutase
BR212012031500U2 (pt) composições sólidas
BR112014010206A2 (pt) composto, composição farmacêutica, uso de composto, e, método para a profilaxia ou tratamento de um estado ou condição de doença
BRPI0813866A2 (pt) Vacinas contra influenza com baixo teor de aditivos
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
LT2596786T (lt) Eikozapentaeno rūgšties etilo esterio naudojimas hipertriglicidemijai gydyti
WO2011113013A3 (en) Methods and compositions for treating viral or virally-induced conditions
BR112013016897A2 (pt) composição oftálmica aquosa
BR112014010179A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para a profilaxia ou tratamento de um estado ou condição
BRPI1007619A2 (pt) "sistema para prevenção de quedas adequado para ser usado por um usuário e métoddo de operação de um sistema para prevenção de quedas que seja usado pelo usuário"
CL2012002422A1 (es) Método para tratar artritis por lupus activo que comprende administrar al paciente laquinimod o su sal sódica por vía oral.
BR112012028719A2 (pt) composição de tratamento de superfície dura, método para fornecer um efeito antimicrobiano a uma superfície dura e uso de uma combinação
CL2014001157A1 (es) Metodo para tratar un ataque de gota que comprende administrar un compuesto de formula (i) y un segundo agente de reduccion de urato.
WO2012154122A3 (en) A topical formulation for treatment of hyperkeratotic skin
BR112012019351A2 (pt) composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica.
BR112014020113A8 (pt) Composições farmacêuticas e método para diminuir a frequência de micção
EA201290373A1 (ru) Синергическая противовирусная композиция и ее применение
BR112012015084A2 (pt) composição farmacêutica de liberação lenta de iloperidone
UY33530A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]